Afuco™ Anti-IFNA1 ADCC Therapeutic Antibody (Rontalizumab), ADCC Enhanced

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IFN alpha. Rontalizumab is a humanized monoclonal antibody. for treatment of systemic lupus erythematosus.
Supplier Creative Biolabs
Product # AFC-TAB-074
Pricing Inquiry
Host Human
Target IFNA1
Species Reactivity Human
Type ADCC enhanced antibody
Applications ELISA, FC, IP, FuncS, IF, Neut
Storage Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Feedback